Technical Information

TI/EVF 1009 e March 2011

Page 1 of 2

Supersedes edition dated August 2010

Plastic Additives



® = registered Trademark of BASF SE

Tinuvin® B 75

Liquid light stabilizer system

Characterization

Tinuvin B 75 is liquid heat and light stabilizer system designed for polyurethanes

Chemical name

Synergistic blend of 20 % Irganox 1135 + 40 % Tinuvin 571 + 40 % Tinuvin 765

CAS number

Preparation

Chemical formula

Irganox 1135

Tinuvin 571

Tinuvin 765

N N

O (CH₂)₄

Molecular weight

390 g/mol

394 g/mol

508 g/mol

Applications

Tinuvin B 75 is used in polyurethanes such as Reaction Injection Molding (RIM) polyurethane and thermoplastic polyurethane (TPU). The blend can also be used in sealant and adhesive applications, in polyurethane coating on tarpaulin and flooring as well as in synthetic leather.

Features/benefits

Tinuvin B 75 prevents the processing, light and weather induced degradation of polyurethane products such as shoe soles, instrument and door panels, steering wheels, window encapsulations, head and arm rests.

Tinuvin B 75 can be easily added to aromatic or aliphatic polyurethane systems for thermoplastic moldings, semi-rigid integral foams, in-mold skinning, dope applications. It can be used with natural and pigmented materials. Tinuvin B 75 is particularly suitable for preparing light stable color pastes for the above mentioned systems.

Additional benefits:

- easy to pump, pourable liquid allowing dust free handling, automated dosage and shortening of mixing time
- all liquid package; no sedimentation of additives in the polyol phase even at low temperatures
- resistant to exudation/crystallization in many PUR systems

Product forms

Clear, slightly yellow liquid

Guidelines for use

The use levels of Tinuvin B 75 range between 0.2 % and 1.5 %, depending on the substrate and performance requirements of the final application:

Reactive two-component integral foams $\begin{array}{ll} 0.6\%-1.5\%\\ \text{Adhesives} \\ \text{Sealants} \\ \end{array}$

Extensive performance data of Tinuvin B 75 are available for many applications.

Physical Properties

Boiling Point > 200 °C Flashpoint > 90 °C Density (20 °C) 0.95–1.0 g/ml

Solubility (20 °C)	g/100 g solution
Acetone	>50
Benzene	>50
Chloroform	>50
Ethyl acetate	>50
Water	< 0.01

Handling & Safety

Tinuvin B 75 exhibits a very low order of oral toxicity and does not present any abnormal problems in its handling or general use.

Detailed information on handling and any precautions to be observed in the use of the product(s) described in this leaflet can be found in our relevant health and safety information sheet.

Note

The descriptions, designs, data and information contained herein are presented in good faith, and are based on BASF's current knowledge and experience. They are provided for guidance only, and do not constitute the agreed contractual quality of the product or a part of BASF's terms and conditions of sale. Because many factors may affect processing or application/use of the product, BASF recommends that the reader carry out its own investigations and tests to determine the suitability of a product for its particular purpose prior to use. It is the responsibility of the recipient of product to ensure that any proprietary rights and existing laws and legislation are observed. No warranties of any kind, either expressed or implied, including, but not limited to, warranties of merchantability or fitness for a particular purpose, are made regarding products described or designs, data or information set forth herein, or that the products, descriptions, designs, data or information may be used without infringing the intellectual property rights of others. Any descriptions, designs, data and information given in this publication may change without prior information. The descriptions, designs, data and information furnished by BASF hereunder are given gratis and BASF assumes no obligation or liability for the descriptions, designs, data or information given or results obtained, all such being given and accepted at the reader's risk.

March 2011